stockrow
Friday 6 November 2026
Export CAI’s income statement to Excel — free account
Caris Life Sciences,�Inc.
Caris Life Sciences,�Inc.’s revenue for fiscal 2025 (year ended December 2025) was $812.0 million, up 97.0% from fiscal 2024.
- Revenue
- +27.0%
- EPS
- −40.3%
- Free cash flow
- −140.2%
- Total debt
- +4.46%
Quarter to September 2026, against a year earlier
24.58
1.45
−5.57%
Follow CAI
Alert me
Caris Life Sciences,�Inc. (CAI) Free cash flow
Caris Life Sciences,�Inc.'s free cash flow for fiscal 2025 was $66.9M, compared with −$253.6M in fiscal 2024. Over the twelve months to 30 September 2026 it was $83.9M. Caris Life Sciences,�Inc. ranks 31st of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $66.9M | — |
| FY2024 | −$253.6M | — |
| FY2023 | −$298.4M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | −$22.2M | — |
| Jun 2026 | $6.4M | (71.59%) |
| Mar 2026 | $22.5M | (43.22%) |
| Dec 2025 | $39.7M | (28.27%) |
| 7 more quarters | Free account |
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| KRYS Krystal Biotech, Inc. compare | $310.1M |
| PTGX Protagonist Therapeutics, Inc. compare | $130.6M |
| CAI Caris Life Sciences,�Inc. | $83.9M |
| TGTX TG Therapeutics, Inc. compare | $17.4M |
| TWST Twist Bioscience Corporation compare | −$95.6M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$168.7M |
| SYRE Spyre Therapeutics, Inc. compare | −$249.3M |
| IBRX ImmunityBio, Inc. compare | −$288.1M |
| CYTK Cytokinetics, Incorporated compare | −$588.6M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on CAI
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Shares outstanding
- Book value per share
- The full statement